Regulatory affairs, causal inference, safe and effective health care in machine learning for Bio-statistical services –

1. AN OVERVIEW OF REGULATORY AFFAIRS, CAUSAL INFERENCE, SAFE AND EFFECTIVE HEALTH CARE IN MACHINE LEARNING FOR BIO- STATISTICALSERVICES An Academic presentationby Dr.NancyAgens,Head,TechnicalOperations,Pubrica Group: www.pubrica.com Email:sales@pubrica.com

2. Today'sDiscussion Outline In Brief Introduction Regulations for Safe and Effective Health Care Machine Learning Limitations TransferLearning Biomarkers in FDA Conclusion

3. In-Brief Over the past few years, the magnitude of machine learning in the field of healthcare delivery setting becomes plentiful andcaptivating. Many regulatory sectors noticing these developments and theFDAhas been appealing to provide bet machine learning services with safe and productive use. Despite having the limitations in software-driven products, FDA leads to giving a significant benefit of causal inference for the development of machine learning. FDA is giving suggestions to provide well equipped regulated products. Pubrica is here to help you with the regulated for Bio-statistical consultingservices.

4. The significance of machine learning hasevolved globally, especially in th field of medical and healthcaresectors. Many tools are significant for various purposes likes diagnosis, software tools for many clinical findingsin multipleareas. The machine learning paves an easier way toclinical Bio-statistical servicesusing many softwaretools. Introduction Contd..

5. It creates an excellent standard on radiology and cardiology and improves the patient’s medical issues rapidly, more comfortable decision making in clinicaltrials. All these maintained by drafting a set of regulationsby various government sectors around theworld. Contd..

6. CAUSALITY MATTERSIN MEDICALIMAGING

7. FDA is a regulatory organization there toperform the quality of any medical or clinical testing equipment, medicines, or any food-related products. Regulations for Safe andEffective Health Care MachineLearning FDA is looking to provide the best facilitiesin health care sectors through machine-learning artificial intelligence services for the statistical programming services. 1. FDA(foodandDrug Administration) Though it is not an urgent need for ML-driven tools, there are few benefits of usingML-driven tools in medical fields, saysFDA Contd..

8. 2.Applications Instrumentalusage Machineimplementation Invitro reagents implantationtechnology Diagnostickit Treatment for humans andanimals. Contd..

9. 3. FDAdefinition The usage of ML can provide both physical equipment and softwaretools. This software device is known as SiMD (software in a medicaldevice). International medical device regulators verify these software-driventools. Contd..

10. 4.Challenges inSiMD Cybersecurity Management ofdata Collection ofdata Protectinginformation To create opportunities in patient’scare

11. Limitations For some reasons, the FDA does not regulatetwo applications of ML systems. Theyare Clinical design supportsoftware(CDS) Laboratory developedtests. The actual reason for exempting these uses areCDS provide instance decision making, which may affect in thefuture. On the other side Laboratory, developed testscan access only one available healthcare. FDA cannot regulate these type ofsoftware. Contd..

12. Last year FDA released a paper after conducting a serious discussion with the regulatory members and proposed “Regulatory Framework for Modificationsto Artificial Intelligence/Machine Learning(AI/ML)-based Software as a MedicalDevice.” For statistics in clinical research. It includes some premarket researchproducts approval procedures that would delay the MLprocess. ManyBio-statistical firmsraised few critics againstit. The objective of the proposal is to give access to real-world data using MLproducts more efficiently with some regulatorybarriers. Contd..

13. The objective of the proposal is to give access to real-world data using ML products more efficiently with some regulatorybarriers. It also includes some real-worldaffirmations. To overcome this, the FDA officials spoke to the public to create awarenessabout the “approach of regulatingalgorithms”. Regardless of all benefits and limitations, ML is facing challenges in the development of the safe and efficient product. Some of the challengesare Contd..

14. MLidentifications MLpredictions MLrecommendations ML algorithms for diagnostic tools To overcome this, Subbaswamy and Saria provide some potential remedies by discussing the statistical foundations intheBio-statistical analysis. Data curation of individual patient’s health raises questions for request algorithms to give a more specific context.

15. The process of learning a task from the already- completed job through knowledge transfer iscalled transferlearning. Transfer Learning However, this process iscomplicated. The datasets can affect the algorithms, resulting in the false provisional services in health careanalysis. This process is not allowed in the medicalsectors.

16. In the process of validation of abiomedicaltool, biomarker validation is mandatory inthe clinical researchservices. Biomarkers inFDA There are so many parameters for qualifyinga biomarker. The casual inference is a noveldigital biomarkervalidation. An ML algorithm that detects the patient’s therapy benefits may not be relevant unless a casual inference tool access in thatbiomarker. Contd..

17. Some make a precise diagnosis and treatment recommendations to understand the factorsinML algorithms. The production of digital biomarkers facing more challenges to incentivizing parties in health care sectors. R&D validated provide significance in delivery of healthcareservices. Studies say that statistician’s tool kit has grown fast, and various technical tools have a development for causal inferenceofmachine learningin biomedicalinvestigations and reviews.

18. Conclusion Wrapping up, in a complex environment, the role of regulatory affairs in biomedical studies for machine learning isessential. One of the easiest ways to support the regulators is the usage of biomarkers in healthcaretools. These regulations help to provide better healthcare services under the guidance ofpubrica.

19. ContactUs UNITEDKINGDOM +44-1143520021 INDIA +91-9884350006 EMAIL sales@pubrica.com